mRNA-1273 at 50 µg dose level induced robust antibody responses of more than 40 times against the Delta variant (B.1.617.2)
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)
According to findings from a new U.K. study, along with reducing the risk of severe disease and hospitalization, COVID-19 vaccines can also lower the odds of having long-term COVID-19 symptoms.